Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new method of experimental treatment for cutaneous
squamous cell skin cancer, using small adhesive-like patches (a micro-needle applicator or
MNA for short), which have dozens of very small micro-needles loaded with extremely low doses
of doxorubicin, a chemotherapy agent. The overall goal of this study is to test the safety
and effectiveness of these patches. The investigators have established the highest tolerated
dose at 50 micrograms in a previous study for a different type of cancer that affects the
skin. The investigators will thoroughly evaluate the skin where the patches are applied.